Large-scale testing (Phase 3)Study completedNCT01377012
What this trial is testing
Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Anti-TNFα Agents
Who this might be right for
Rheumatoid Arthritis
Novartis Pharmaceuticals 637